Working with our clients, we have built an experienced team within Sundia. We have established over 50 in vitro cell lines for oncology targets, and we have set up more than 30 xenograft models in-house.
Over the last couple of years, we have brought several oncology projects from starting concept to clinical compound by working with our clients in a timely and cost-effective manner.
Our unique high potency facility and formulation capability are benefits to our clients.
Our computational aid drug design (CADD) has the tools, including PBSDD technology, to provide meaningful support for cancer targets, such as kinases.
Our molecular diagnostic laboratory can collaborate with MMD to help cancer patients
